Monoclonal antibody · Antagonist of latent TGF-beta 1 (TGFB1) · developed by Scholar Rock
Linavonkibart is a monoclonal antibody that binds and inhibits latent TGF-beta 1, preventing TGF-beta-mediated immunosuppression in the tumor microenvironment. By enhancing anti-tumor immunity and promoting cytotoxic T-lymphocyte responses, it is being studied in cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04291079 | Phase 1 | Cancer | Completed | SRRK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the SRRK page.
See SRRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRRK catalysts and pipeline →